Asthma and lower airway diseaseDistinguishing characteristics of difficult-to-control asthma in inner-city children and adolescents
Graphical abstract
Section snippets
Study design
Asthma Phenotypes in the Inner City (APIC) was a prospective longitudinal study of 6- to 17-year-old children with asthma living in 9 urban areas. Participant selection criteria included residence in an area with greater than 20% of residents below the poverty level, a physician's diagnosis of asthma, at least 2 episodes of short-acting β-agonist administration within the past 12 months (exclusive of use associated with exercise-induced symptoms), and 50% or greater adherence to controller
Results
Between August 2011 and September 2013, 1195 children were recruited, 845 were eligible for screening, and 717 became part of the longitudinal cohort (Fig 2). Of these, 619 (86.3%) completed at least 4 of the 6 bimonthly visits for evaluation and management of asthma and rhinitis and were included in this analysis. Two hundred fifty-three (40.9%) participants met the criteria for difficult-to-control asthma, 232 (37.5%) had easy-to-control asthma, and 134 (21.6%) had indeterminate asthma.
Discussion
This is the first study to date of a large population of children characterized prospectively while receiving guideline-based management for asthma and rhinitis. The unique and novel aspects of the study are its longitudinal assessment of participants to help characterize and establish the stability of the groups over time; inclusion of standardized, guideline-based asthma and rhinitis assessments and computerized management algorithms; and collection of variables in a broad range of domains,
References (38)
- et al.
Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial
Lancet
(2008) - et al.
Development and validation of the Composite Asthma Severity Index—an outcome measure for use in children and adolescents
J Allergy Clin Immunol
(2012) - et al.
Prevalence of allergic sensitization in the United States: results from the National Health and Nutrition Examination Survey (NHANES) 2005-2006
J Allergy Clin Immunol
(2014) - et al.
Development and cross-sectional validation of the Childhood Asthma Control Test
J Allergy Clin Immunol
(2007) - et al.
The Childhood Asthma Control Test: retrospective determination and clinical validation of a cut point to identify children with very poorly controlled asthma
J Allergy Clin Immunol
(2010) - et al.
Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists
J Allergy Clin Immunol
(2006) - et al.
Asthma outcomes: pulmonary physiology
J Allergy Clin Immunol
(2012) - et al.
FEV1 response to bronchodilation in an adult urban population
Chest
(2008) - et al.
Argument for changing criteria for bronchodilator responsiveness
Respir Med
(2008) - et al.
The relationship of the bronchodilator response phenotype to poor asthma control in children with normal spirometry
J Pediatr
(2011)
Allergic rhinitis and its impact on asthma
J Allergy Clin Immunol
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision
J Allergy Clin Immunol
Nocturnal awakening caused by asthma in children with mild-to-moderate asthma in the childhood asthma management program
J Allergy Clin Immunol
Differential effects of outdoor versus indoor fungal spores on asthma morbidity in inner-city children
J Allergy Clin Immunol
Household mouse allergen exposure and asthma morbidity in inner-city preschool children
Ann Allergy Asthma Immunol
Asthma control, adiposity, and adipokines among inner-city adolescents
J Allergy Clin Immunol
Airway obstruction worsens in young adults with asthma who become obese
J Allergy Clin Immunol Pract
Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma
Respir Med
Rhinitis and asthma: evidence for respiratory system integration
J Allergy Clin Immunol
Cited by (0)
This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (under contract nos. HHSN272200900052C and HHSN272201000052I, and 1UM1AI114271-01). Additional support was provided by the National Center for Research Resources (NCRR), and the National Center for Advancing Translational Sciences (NCATS), NIH (under grant nos. NCRR/NIH UL1TR000451, UL1RR025780, UL1TR000075 Q1 and NCATS/NIH UL1TR000154, UL1TR001082, UL1TR000077-04, UL1TR000040, UL1TR000150, and UL1TR001105). GlaxoSmithKline (GSK) provided Ventolin, Flovent, Advair, and Flonase under a clinical trial agreement with NIH NIAID; GSK did not have a role in the development or approval of the protocol, conduct of the trial, data analysis, manuscript preparation, or the decision to submit the manuscript for publication.
Disclosure of potential conflict of interest: J. A. Pongracic has received travel support and a subcontract from the University of Wisconsin; has received writing assistance, medicines, equipment, or administrative support from GlaxoSmithKline; and has received study drugs for other studies from GlaxoSmithKline, Teva, Merck, Boehringer Ingelheim, and Genentech/Novartis. R. Z. Krouse, D. C. Babineau, and C. M. Visness have received grants from the National Institutes of Health (NIH)–National Institute of Allergy and Infectious Diseases (NIAID). E. M. Zoratti, G. K. Khurana Hershey, C. C. Johnson, and S. M. Sigelman have received grants from the NIH. R. A. Wood has received grants from the NIH, DBV, and Aimmune; has consultant arrangements with Sanofi and Stallergenes; is employed by Johns Hopkins University; and has received royalties from UpToDate. C. M. Kercsmar has received a grant from the NIH and was the chair of Data Safety Monitoring Boards on the GlaxoSmithKline funded, US Food and Drug Administration–mandated VESTRI trial evaluating safety of ICS+LABA vs ICS alone in children. R. S. Gruchalla is employed by the Center for Biologics Evaluation and Research and has consultant arrangements with the Massachusetts Medical Society. M. Kattan has received a grant from the NIH-NIAID and is on the advisory board for Novartis Pharma. S. J. Teach has received grants from the NIH-NIAID, Novartis, PCORI, Fight for Children Foundation, EJF Philanthropies, and the NIH–National Heart, Lung, and Blood Institute; has consultant arrangements with Novartis; and has received royalties from UpToDate. L. B. Bacharier has consultant arrangements with Aerocrine, GlaxoSmithKline, Genentech/Novartis, Cephalon, Teva, and Boehringer Ingelheim; has received payment for lectures from Aerocrine, GlaxoSmithKline, Genentech/Novartis, Merck, Teva, Boehringer Ingelheim, and AstraZeneca; has served on the Scientific Advisory Board for Merck; has served on the Data Safety Monitoring Board for DBV Technologies; has received honoraria for CME program development from WebMD/Medscape; and has served on Advisory Boards for Sanofi and Vectura. J. E. Gern has received grants from the NIH and GlaxoSmithKline; has consultant arrangements with GlaxoSmithKline, Genentech, Amgen, Novartis, Janssen, and Regeneron; has received payment for development of educational presentations from Boehringer Ingelheim; and has stock/stock options in 3V Biosciences. W. W. Busse has received a grant from the NIH-NIAID, has received partial study funding and provision of study drug and placebo from Novartis, is a member of the Data Safety Monitoring Boards for Boston Scientific and Circassia, is a member of the Study Oversight Committee for ICON, and has consultant arrangements with Novartis, GlaxoSmithKline, Genentech, Roche, Pfizer, Merck, Boehringer-Ingelheim, Sanofi, AstraZeneca, Teva, Takeda, Aerocrine, and 3M. A. H. Liu has received a grant from the NIH, is a member of the Data Monitoring Committee for an asthma study for GlaxoSmithKline, and has received payment for lectures from Merck. The rest of the authors declare that they have no relevant conflicts of interest.